Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 5/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728677 | 1.00 | TRPV1 (0.47) | TRPV1GPR119USP30ARTRPA1 | |
| SCHEMBL416256 | 0.88 | ALDH1A1 (0.57) | GPR119ARTRPA1MAPTALDH1A1 | |
| SCHEMBL16321232 | 0.86 | TRPA1 (0.49) | ARTRPA1MAPTKMT2AGFER | |
| SCHEMBL29136118 | 0.82 | ALDH1A1 (0.53) | GPR119USP30MAPTKMT2AALDH1A1 | |
| SCHEMBL13238912 | 0.81 | ALDH1A1 (0.53) | GPR119USP30HDAC6MAPTKMT2A | |
| SCHEMBL3038785 | 0.80 | TRPA1 (0.48) | ARTRPA1 | |
| SCHEMBL16321644 | 0.80 | TRPA1 (0.48) | ARTRPA1 | |
| SCHEMBL24781306 | 0.79 | KMT2A (0.59) | TRPV1USP30HDAC4HDAC6MAPT | |
| SCHEMBL16878999 | 0.79 | PDE4B (0.53) | GPR119ARMAPTKMT2AALDH1A1 | |
| SCHEMBL30028550 | 0.79 | KMT2A (0.59) | TRPV1USP30HDAC4HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890139-B2 | CYP17 inhibitors/antiandrogens | ORION CORPORATION (FI) | 2018-02-13 | — | — | US | disclosed |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | CYP17A1, CYP19A1, CYP21A2 | TRPV1 4103/4885GPR119 301/4885USP30 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.